|Clinipace CEO Jeff Williams|
Clinipace has signed a far-reaching deal with biotech Karyopharm Therapeutics ($KPTI), agreeing to handle a host of studies under a preferred provider arrangement.
With the long-term deal, Clinipace is on board to pitch in on development for a bevy of first-in-class therapies targeting cancer, wound healing and other major diseases, the two said. Karyopharm, which pulled off a $109 million IPO in November, is building a pipeline around its technology for inhibiting inner-nucleus transport, and its lead candidate is the cancer-fighting KPT-330.
"As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner," Clinipace CEO Jeff Williams said in a statement, saying his CRO's combination of technology and global reach makes it an ideal match for the biotech.
Meanwhile, the company is still in the midst of integrating its latest acquisition after closing a deal for Hong Kong CRO Choice Pharma last month. Clinipace isn't planning any layoffs or closures with the merger, and once the deal is done the CRO will employ more than 640 people in 30 countries while maintaining its headquarters in Research Triangle Park, NC.
The Choice acquisition is Clinipace's 5th buyout in as many years, following deals for Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.
- read the statement